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Importance 
Canine brucellosis, caused by Brucella canis, is an important cause of 
reproductive failure, particularly in kennels. This organism causes abortions, 
stillbirths, epididymitis, orchitis and sperm abnormalities in dogs. Although dogs that 
have been spayed or neutered do not have reproductive signs, they occasionally 
develop other conditions such as ocular disease and discospondylitis. B. canis can 
persist in an animal even after antibiotic treatment. In kennels, infected dogs are often 
euthanized to prevent them from infecting other dogs or people. Canine brucellosis is 
sometimes difficult to diagnose with the currently available tests. 
Although B. canis is zoonotic, its importance as a cause of human illness is still 
unclear. Few cases have been reported in people, and most of these infections have been 
mild. However, human infections with B. canis may be underdiagnosed. The symptoms 
of this disease are nonspecific, diagnostic suspicion is low among physicians, and 
bacterial culture is the only commonly available test for diagnosis in people. 
Etiology 
In dogs, brucellosis is mainly caused by Brucella canis, a Gram-negative 
coccobacillus or short rod. This organism is a facultative intracellular pathogen. Other 
Brucella species occasionally associated with disease in dogs include Brucella 
abortus, B. melitensis and B. suis. (For information on these organisms, see the 
factsheets titled “Bovine Brucellosis,” “Ovine and Caprine Brucellosis,” and “Porcine 
Brucellosis” respectively.)  
In addition to the organisms found in dogs, humans can be infected with the less 
virulent M- strain of B. canis, which is used as an antigen for serological testing. One 
clinical case was reported in a person exposed to this organism in the laboratory. 
Geographic Distribution 
B. canis appears to be widely distributed. Locations where it has been reported 
include the United States (particularly the southern states), Canada, Central and South 
America (including Mexico), some European countries, Tunisia, Nigeria, South 
Africa, Madagascar, the Philippines, Malaysia, India, Korea, Japan, Taiwan and 
China. New Zealand and Australia appear to be free of this organism. 
Transmission 
B. canis occurs in the fetus, placenta, fetal fluids and vaginal discharge after an 
abortion or stillbirth. It can persist in vaginal discharges for several weeks after an 
abortion. It is also shed in normal vaginal secretions, particularly during estrus, as well 
as in milk. High concentrations of B. canis may be found in semen for weeks or months 
after infection, and intermittent shedding of smaller quantities can occur for years. B. 
canis is also shed in urine, and low concentrations of bacteria may be excreted in saliva, 
nasal and ocular secretions, and feces.  
In dogs, B. canis primarily enters the body by ingestion and through the genital, 
oronasal and conjunctival mucosa, but transmission through broken skin may also be 
possible. Most cases are thought to be acquired by venereal transmission or by contact 
with the fetus and fetal membranes after abortions and stillbirths. Puppies can be 
infected in utero, and may remain persistently infected even if they appear normal. 
Nursing puppies can be infected from milk, but the importance of this route is 
controversial. Other potential sources of infection include blood transfusions and 
contaminated syringes.  
B. canis can be spread on fomites. In conditions of high humidity, low 
temperatures and no sunlight, Brucella spp. can remain viable for several months in 
water, aborted fetuses, feces, equipment and clothing. Brucella species can withstand 
drying, particularly when organic material is present, and can survive in dust and soil. 
Survival is longer when the temperature is low, particularly when it is below freezing. 
Humans usually become infected with members of the genus Brucella by 
ingesting organisms or via the contamination of mucous membranes and abraded 
skin. In case reports, B. canis infections have been described after close contact with  
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dogs, especially animals that recently aborted or gave 
birth, and after exposure to large amounts of the organism 
in laboratories (e.g., contact with bacterial cultures). 
However, the source of the organism could not be 
determined in some cases. 
Disinfection  
Brucella species are readily killed by most commonly 
available disinfectants including hypochlorite solutions, 
70% ethanol, isopropanol, iodophores, phenolic 
disinfectants, formaldehyde, glutaraldehyde and xylene; 
however, organic matter and low temperatures decrease the 
efficacy of disinfectants. Disinfectants reported to destroy 
Brucella on contaminated surfaces include 2.5% sodium 
hypochlorite, quaternary ammonium compounds, 2-3% 
caustic soda, 20% freshly slaked lime suspension, or 2% 
formaldehyde solution (all tested for one hour). Ethanol, 
isopropanol, iodophores, substituted phenols or diluted 
hypochlorite solutions can be used on contaminated skin; 
alkyl quaternary ammonium compounds are not 
recommended for this purpose. Autoclaving [moist heat of 
121°C (250°F) for at least 15 minutes] can be used to 
destroy Brucella species on contaminated equipment. These 
organisms can also be inactivated by dry heat [320-338°F 
(160-170°C) for at least 1 hour]. Boiling for 10 minutes is 
usually effective for liquids. Brucella species can also be 
inactivated by gamma irradiation. 
Infections in Humans 
Incubation Period 
There is little information on the incubation period for 
brucellosis caused by B. canis. Relatively few cases have 
been documented, and in many cases reported in the 
literature, exposure was ongoing or the source was 
unknown. The symptoms caused by other Brucella spp. 
usually appear within 2 weeks of exposure, but some cases 
have developed as late as 3 months.  
Clinical Signs 
The virulence of B. canis for humans has been 
considered to be low, as few cases have been documented 
and most have been mild. However, infections may be 
underreported; specific diagnostic tests are rarely performed, 
and this disease can be difficult to diagnose. 
Because few descriptions of human B canis infections 
have been published, the expected clinical signs are based 
mainly on the syndromes caused by other species of 
Brucella. Some people infected with Brucella spp. remain 
asymptomatic. In symptomatic cases, the disease is 
extremely variable and the clinical signs may appear 
insidiously or abruptly. Typically, brucellosis begins as an 
acute febrile illness with nonspecific flu-like signs such as 
fever, chills, headache, malaise, back pain, myalgia and 
generalized aches. Drenching sweats can occur, particularly 
at night. Some patients may also have lymphadenopathy, 
splenomegaly or hepatomegaly. Some patients with 
brucellosis recover spontaneously, while others develop 
persistent symptoms that typically wax and wane and may 
include fever, weakness and other nonspecific signs. 
Occasionally seen complications include arthritis, 
spondylitis, chronic fatigue and epididymo-orchitis. 
Neurologic signs (including personality changes, 
meningitis, uveitis and optic neuritis), anemia, internal 
abscesses, nephritis, vasculitis, endocarditis and dermatitis 
have been reported with some species of Brucella. Other 
organs and tissues can also be affected, resulting in a wide 
variety of syndromes. The mortality rate for brucellosis 
(which includes the disease caused by highly virulent 
organisms such as B. melitensis) is low; in untreated 
persons, estimates of the case fatality rate vary from less 
than 2% to 5%. Deaths are usually caused by endocarditis 
or meningitis. 
Published infections with B. canis have included a 
variety of clinical signs and presentations consistent with 
this description. They range from mild fatigue, or fatigue 
and intermittent fever as the only symptoms, to a febrile 
illness with fatigue, malaise, nausea, chills, night sweats 
and headache. Fever of unknown origin, sometimes 
prolonged, was the presenting syndrome in some 
individuals. Enlargement of the spleen was reported in 
several cases. Weight loss, enlarged lymph nodes, 
abdominal pain, an enlarged liver and signs of liver 
dysfunction have also been documented. Nausea, vomiting 
and diarrhea have been described, especially in children, 
and one individual reported persistent cough, sore throat 
and conjunctival burning (in addition to night sweats, 
headache, lethargy and myalgia). Oral lesions were found in 
a child concurrently infected with B. canis and 
cytomegalovirus, and resolved with antibiotic treatment for 
brucellosis. Serious syndromes including endocarditis have 
been reported in a few cases. B canis was associated with 
aortic valve vegetations and lower extremity aneurysms in 
one boy, and calvarial osteomyelitis, epidural abscess, 
pleural effusion and pulmonary nodules in another child. 
Some conditions seen in other Brucella infections, such as 
epididymo-orchitis and neurological signs, have not been 
reported with B. canis as of 2012. This might be due either 
to the few cases known, or because this species is usually 
less pathogenic for humans than livestock Brucella. Some 
illnesses caused by B. canis persisted for several months 
before diagnosis. A few patients also relapsed with 
inadequate treatment.  
A laboratory worker exposed to the less virulent M-
strain of B. canis developed symptoms similar to those 
caused by wild-type strains of Brucella. 
Two B. canis infections were diagnosed in people 
infected with HIV-1. B. canis was found in the blood of one 
patient with a febrile syndrome. In another individual, the 
presenting signs included high fever, malaise, arthralgia and 
loose stools, with a 5 month history of low-grade fever, 
fatigue, arthralgia, myalgia and night sweats.  
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Communicability 
There is no information about the communicability of 
B canis in humans. Other species of Brucella are not 
transmitted between people by casual contact, and 
transmission by other routes is unusual, though it can occur 
(e.g., by blood transfusion, accidental ingestion of 
contaminated material, or sexual intercourse). 
Diagnostic Tests 
Brucellosis caused by B. canis can be difficult to 
diagnose in humans. The symptoms are nonspecific, and 
few diagnostic tests are available. B. canis can sometimes 
be found in blood, and some cases have been detected when 
this organism was unexpectedly isolated during routine 
blood culture. However, B. canis grows slowly, and it may 
not appear within the time that blood cultures are routinely 
held. Overgrowth by other organisms may also prevent its 
detection in samples taken from non-sterile sites. 
Antibiotics can inhibit the growth of B. canis, even when 
the dose or type of antibiotic is not curative in the patient. 
The serological tests used routinely to diagnose human 
infections with B. abortus, B. suis and B. melitensis do not 
detect antibodies to B. canis. These tests use “smooth 
phase” antigens (“smooth” lipopolysaccharide in the cell 
wall); however, B. canis is a “rough” form of Brucella. 
Reagents are not produced commercially for human B. 
canis tests, and serological tests for this organism are not 
performed routinely by diagnostic laboratories. In some 
reports in the literature, antibodies to B. canis were detected 
with tests developed for this purpose or adapted from 
canine assays at the institution. Most of these assays were 
agglutination tests. They included microagglutination, tube 
agglutination and the rapid slide agglutination test
 
(RSAT). 
One group developed an indirect enzyme-linked 
immunosorbent assay (ELISA), and a serological study 
from the 1970s used agar gel immunodiffusion (AGID) for 
B. canis surveillance in humans. Cross-reactions can occur 
between Brucella and some other microorganisms in 
serological tests. Nonspecific reactions can also result in 
false positive agglutination. Some published case reports 
suggest that clinical resolution is associated with declining 
antibody titers to B. canis.  
Relying on a single type of test (i.e., either culture or 
serology) may miss some infections. In the literature, B canis 
was not always found in the blood of some patients identified 
by serology, and conversely, serology did not always detect 
antibodies in people who had B. canis in the blood.  
Treatment 
Brucellosis in people is usually treated with an 
prolonged course combining two antibiotics. Different 
antibiotics may be recommended, depending on the 
patient’s age and pregnancy status. Relapses can be seen if 
treatment is inadequate. Most occur within four to six 
months after the treatment ends.  
There is only limited experience with the treatment of 
B. canis; however, standard antibiotic treatments for 
brucellosis resulted in good responses and successful 
resolution in published cases. Two patients who were not 
given brucellosis-specific treatments, but had gradually 
improved on other antibiotics, experienced relapses. Their 
illnesses resolved with standard brucellosis-specific 
antibiotics. Another patient experienced two relapses before 
an extended 4-month treatment resulted in the 
disappearance of antibodies to B. canis and no further 
symptoms during a two year follow-up.  
Prevention 
Potential hazards to people should be discussed when 
brucellosis is diagnosed in a dog, as antibiotics do not 
reliably eliminate B. canis, and the level of risk to human 
companions is currently uncertain. Euthanasia of infected 
animals is usually recommended in kennels, and it is also 
an option in pets. Some authors recommend periodic 
serological monitoring of treated pets, to detect rising 
immune responses from recrudescence. Good hygiene is 
also likely to decrease human exposure, especially during 
births and abortions, but also during contact with urine, 
vaginal secretions and other potential sources of B. canis. 
Prophylactic antibiotics may be prescribed for 
laboratory workers in some situations. 
Morbidity and Mortality 
There is little information about B. canis infections in 
humans. Although these infections are thought to be 
uncommon or rare, with only 18 documented cases between 
1967 and 1982, they also appear to be underdiagnosed. 
Case reports in the literature describe infections in 
immunocompetent, healthy people and in individuals 
infected by HIV-1. Two disease clusters were recently 
reported in the literature. One occurred in two pet shop 
workers in Japan, probably as a result of handling an 
aborted canine fetus without protection. No other 
individuals who had contact with these two patients or with 
six infected dogs had evidence of exposure or illness. Those 
examined included colleagues at the pet shop, family 
members, laboratory workers who handled cultures, and a 
veterinarian. In a cluster of cases from Buenos Aires, three 
young children and three adults from two households 
became infected after close, regular contact with a pet dog 
and/or her three puppies. One of the three children was ill, 
while two had laboratory abnormalities or enlargement of 
the spleen at examination. All three children were treated 
with antibiotics. Two adults had serological evidence of 
exposure, but did not require treatment, and one adult 
described possible symptoms but declined clinical 
examination. The dogs were removed from the households, 
and the antibody titers in the people decreased over time. 
In 2011, a serological study was conducted in patients 
who had signs consistent with brucellosis in Turkey. 
Among these patients, 8.9% were seropositive for B. canis 
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in a RSAT test, 3.7% were seropositive by a 2-
mercaptoethanol RSAT (this test detects IgG and not IgM) 
and 3.8% by a microagglutination test. Some of these 
reactions were reported to be false positives, but false 
negatives were also found. In another recent Turkish study, 
which used a slide agglutination test (SAT) confirmed by 2-
mercaptoethanol SAT, the seroprevalence was 1.6% among 
healthy blood donors. 
A number of serological surveys were conducted in the 
1970s and early 1980s. Most of these studies found a low 
rate of reactors, but a few reported higher seroprevalence 
rates. In a German study, less than 0.5% of serum samples 
from blood donors (1400 samples) had antibodies to B. 
canis. No samples from clinical patients (480 samples), 
people exposed to dogs or infectious material (35 samples), 
veterinarians and assistants (16 samples) or animal 
caretakers (19 samples) were seropositive. The samples 
were tested by agglutination, and positive results were 
confirmed by complement fixation and indirect 
immunofluorescence. In the U.S., the seroprevalence was 
reported to be 0.4% in military recruits aged 18-26 (using an 
experimental tube agglutination test), and 0.6% in Florida 
residents. In contrast, a 1975 study from the Oklahoma 
Health Sciences Center reported an overall seroprevalence 
of 68% in people “with an average exposure to dogs,” 73% 
in veterinarians, and 57% in male blood donors, using a 
microtiter technique to detect B. canis antibodies. In 
Mexico, 13% of hospitalized patients with various illnesses 
had antibodies to B. canis. In Argentina, 2% of individuals 
were seropositive in house-to-house surveillance, using 
AGID with a B. ovis antigen, and 0.2% were seropositive in 
a survey of rural schools.  
Infections in Animals 
Species Affected 
B. canis is only known to be important in dogs. 
Antibodies to this organism have been reported 
occasionally in wild canids including foxes and coyotes, as 
well as in one raccoon (Procyon lotor). Experimental 
infections have been established in chimpanzees (Pan 
troglodytes), stumptail macaques (Macaca arctoides), 
rhesus macaques (Macaca mulatta), mice, rabbits and 
guinea pigs. Sheep, swine and cattle were reported to be 
highly resistant to experimental infection by oral and 
conjunctival inoculation; however, two field infections with 
B. canis have been reported in cattle. After oral inoculation, 
three of 14 experimentally infected cats developed 
bacteremia, but agglutinating antibodies were not detected. 
Incubation Period 
The period between infection and reproductive signs is 
variable; abortions are most common at approximately 7-9 
weeks of gestation. Early embryonic deaths have also been 
reported two to three weeks after venereal transmission.  
Clinical Signs 
B. canis can cause abortions and stillbirths in pregnant 
dogs. Most abortions occur late, particularly during the 
seventh to the ninth week of gestation. Abortions are 
usually followed by a mucoid, serosanguinous or gray-
green vaginal discharge that persists for several weeks. 
Early embryonic deaths and resorption have been reported 
a few weeks after mating, and may be mistaken for failure 
to conceive. Some pups are born live but weak. These 
pups often die soon after birth. Other congenitally infected 
pups can be born normal and later develop brucellosis. 
Clinical signs occur during subsequent pregnancies in 
some dogs, but not in others.  
The sperm may have morphological abnormalities and 
reduced viability in some infected males. Epididymitis and 
scrotal edema are common in the acute stage, and orchitis 
may be seen. Scrotal dermatitis can occur due to self-
trauma (e.g., licking). Unilateral or bilateral testicular 
atrophy can be seen in chronic infections, and some males 
become infertile. Prostatitis may lead to pain and difficult 
urination and defecation. 
Lymphadenitis is common in infected dogs. The 
retropharyngeal lymph nodes may enlarge after oral 
infection, and the superficial inguinal and external iliac 
nodes after vaginal infection. Generalized lymphadenitis is 
also common. Other symptoms that are occasionally 
reported include lethargy or fatigue, exercise intolerance, 
decreased appetite, weight loss and behavioral 
abnormalities (loss of alertness, poor performance of tasks); 
however, most affected dogs do not appear seriously ill. 
Occasionally, discospondylitis of the thoracic and/or 
lumbar vertebrae can cause stiffness, lameness or back pain. 
Chronic uveitis, endophthalmitis, polygranulomatous 
dermatitis, endocarditis, osteomyelitis related to hip 
prostheses, and meningoencephalitis/ low grade meningitis 
have also been reported. Fever is rare. Many infected dogs 
remain asymptomatic. 
Dogs with brucellosis may recover spontaneously, 
beginning a year after infection, but recovery is more 
common after two to three years, and some dogs remain 
chronically infected for years. Deaths are rare except in the 
fetus or newborn.  
Post Mortem Lesions 
The lymph nodes are often enlarged in affected animals. 
The retropharyngeal and inguinal lymph nodes are often 
involved, but generalized lymphadenitis also occurs. The 
spleen is frequently enlarged, and may be firm and nodular. 
Hepatomegaly may also be seen. Scrotal edema, scrotal 
dermatitis, epididymitis, orchitis, prostatitis, testicular 
atrophy and fibrosis are common in males, and metritis and 
vaginal discharge may be seen in females. Less commonly 
reported lesions include discospondylitis, meningitis, focal 
non-suppurative encephalitis, osteomyelitis, uveitis and 
abscesses in various internal organs. 
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Aborted puppies are often partially autolysed and may 
have evidence of generalized bacterial infection. These 
lesions can include subcutaneous edema, subcutaneous 
congestion and hemorrhages in the abdominal region, 
serosanguinous peritoneal fluid, and degenerative lesions in 
the liver, spleen, kidneys and intestines. 
Communicability 
B. canis is shed in semen, with the highest concentration 
during the first six months after infection, and it may be 
excreted intermittently for years. In addition to natural 
mating, this organism can be transmitted by artificial 
insemination with fresh, chilled or frozen semen. Other 
sources of B. canis include the fetus, placenta, fetal fluids and 
vaginal discharge after an abortion or stillbirth, as well as 
normal vaginal secretions, particularly during estrus. Urine 
and other body fluids and excretions can contain B. canis. 
Chronically infected dogs can shed this organism despite 
being seronegative and blood culture negative.  
Uninfected dogs living with infected animals of the 
same sex were found to acquire the infection within 6 
months.  
Diagnosis 
Canine brucellosis should be considered in dogs with 
reproductive conditions; however, some infected dogs are 
asymptomatic or have only nonspecific signs such as 
lymphadenitis. Focal signs such as discospondylitis or 
uveitis can also occur in spayed or neutered animals. 
Canine brucellosis is sometimes difficult to diagnose, and 
the best chance of success is if multiple techniques (e.g., 
culture, PCR and serology) are used in combination.  
The rapid slide agglutination test (RSAT) and the tube 
agglutination test (TAT) are often used to detect antibodies 
to B. canis in dogs. The RSAT is a rapid commercial test 
that can be used for screening. Adding 2-mercaptoethanol 
(2-ME) to these assays (i.e., the 2-ME RSAT or 2-ME 
TAT) improves specificity by dissociating IgM, which is 
more likely  than IgG to cross-react with other bacteria. 
However, this can also decrease sensitivity, especially 
during the early stage of the immune response when IgM 
predominates. Other serological tests that have been used 
either clinically or in research include AGID, ELISA, an 
indirect fluorescent antibody (IFA) test, complement 
fixation, a lateral flow immune-chromatographic assay 
(LFIA) and counter-immunoelectrophoresis. Positive 
reactions in some screening tests, such as RSAT, are often 
confirmed with a more specific assay. Titers vary between 
individuals and with the detection method.  
A number of factors should be considered when using 
serological tests to diagnose B. canis infections, False 
positive reactions can be a problem, as cross-reactions can 
occur between this organism and other Gram-negative 
bacteria such as Bordetella and Pseudomonas. Nonspecific 
agglutination reactions can also occur. Conversely, 
antibodies to B. canis may be absent in dogs during the 
early stages of the infection (i.e., before the development of 
antibodies), as well as in chronically infected animals. 
Some tests, such as RSAT, have a reputation for a high 
incidence of false positives. However, a recent study found 
that some reactions which would be classified as false 
positives, based on culture and clinical signs alone, occur in 
animals that are positive by PCR. 
A definitive diagnosis can be made if B. canis is 
cultured from an animal. Brucella spp. can be isolated on a 
variety of plain media, or selective media such as Farrell's 
medium or Thayer-Martin’s modified medium. Enrichment 
techniques can also be used. B. canis colonies are naturally 
rough (R) or mucoid (M). This organism grows slowly, 
making detection more difficult. Bacterial overgrowth can 
be a problem in nonsterile samples. Blood cultures are often 
used to detect B. canis. Bacteremia can be intermittent, and 
the number of organisms in the blood may be low. 
Repeated culture may be necessary for isolation. Samples 
from the genital tract (e.g., semen, vaginal discharges, 
placenta) are often more useful than blood, especially in 
animals with reproductive signs. B. canis may also be 
detected in milk, urine and aborted fetuses (gastric contents, 
liver, spleen), as well as in tissues such as the lymph nodes, 
spleen, prostate, epididymis, testis, uterus, liver and bone 
marrow, and clinically affected vertebrae or eyes. Bacteria 
are not always found, especially in chronically infected 
dogs. Antibiotics can also interfere with culture.  
B. canis colonies can be identified by phenotypic 
methods or genetic techniques. The ‘Bruce-ladder’ 
multiplex PCR assay, which can be used to distinguish 
species of Brucella, sometimes misidentifies B. canis as B. 
suis. Methods to solve this problem, including substitution 
of a pair of primers in the Bruce-ladder assay, and a new 
multiplex conventional PCR assay (Suis-ladder) have been 
published. Single nucleotide polymorphism (SNP) typing 
has also been reported to correctly identify B. canis.  
Real-time polymerase chain reaction (PCR) assays can 
be used to detect B. canis in samples such as semen, urine, 
and vaginal and uterine swabs. PCR can also be attempted 
on whole blood.  
Treatment 
Some affected dogs have been treated successfully with 
long-term antibiotics. Treatment usually requires a 
combination of two different antibiotics, but enrofloxacin 
alone appeared to be successful in one trial. A few case 
reports have also documented the successful treatment of 
chronic or recurrent endophthalmitis caused by B. canis. 
No treatment is certain to eliminate B. canis. Even 
when this organism seems to have disappeared, it may 
persist in tissues such as lymph nodes, spleen, uterus and 
prostate. Recrudescence is possible, especially when an 
animal is stressed. For this reason, euthanasia of infected 
animals is often recommended in kennels, and this option 
should also be discussed when the disease is found in a pet. 
Neutering can be used as an additional control measure in 
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treated animals, if they are intact. Periodic serological 
monitoring may be able to detect rising antibody titers 
during recrudescence.  
Prevention 
Canine brucellosis is usually introduced into a kennel 
in an infected dog or semen. New animals should be 
isolated and tested before adding them to the general 
population. A second serological test, performed before 
release from quarantine, may detect animals that are in the 
early stage of the infection and seronegative on arrival. 
Due to the difficulties in brucellosis testing, some infected 
animals may not be identified. It has also been 
recommended that dogs be tested before allowing them to 
breed. Some authors recommend testing all dogs in a 
kennel, either annually or twice a year. This may reduce 
losses in the event that B. canis is introduced.  
In infected kennels, brucellosis can be controlled by 
sanitation and infection control measures, together with 
the euthanasia, isolation or removal (e.g., to a research 
facility) of infected dogs. Housing in individual cages 
reduces the spread of the organism. Dogs from infected 
kennels should not be sold or used for breeding. Repeated 
testing and removal of infected animals, combined with 
quarantine and testing of newly added dogs, has been used 
to eradicate brucellosis from some kennels. There is no 
vaccine for B. canis. 
Morbidity and Mortality 
All breeds of dogs are susceptible to canine brucellosis. 
B. canis spreads rapidly in confined populations, especially 
during breeding or when abortions occur. Although death is 
rare, except in the fetus and neonate, significant 
reproductive losses can be seen, particularly in breeding 
kennels. Up to 75% fewer puppies may be weaned from 
affected kennels.  
The prevalence of canine brucellosis is still incompletely 
understood. In the southern U.S., one author estimated that 
approximately 6% of dogs overall had antibodies to B. canis 
in the 1970s. Several individual surveys at that time reported 
that infections were more common in stray and feral dogs 
than in pets. In one study, 7.6% of the stray dogs and no pets 
on an Air Force Base in Mississippi had antibodies to B. 
canis. A survey from Tennessee found seropositive dogs 
only among free roaming animals and not those that were 
confined. Another survey reported that 9% of mature stray 
dogs but only 1% of pet dogs were seropositive. Among 
dogs tested in animal shelters in Illinois and Wisconsin in 
the 1970s, 6.7% were seropositive in a slide agglutination 
test, 1.5% were seropositive when confirmed by tube 
agglutination, and the organism was isolated from the blood 
of 0.2%. One recent paper mentioned unpublished work 
demonstrating antibodies in less than 2% of stray dogs in an 
animal shelter in Oklahoma, and all of these dogs were 
negative by culture. However, some authors report that the 
prevalence might be rising in some populations. In 
Oklahoma, 2% of domesticated dogs were reported to be 
seropositive in 1994-1995, and 13% in 2002- 2003.  
Antibodies to B. canis have also been found 
occasionally in wild canids in the U.S. In one study, 22% of 
the San Joaquin kit foxes (Vulpes macrotis mutica) tested 
from one region of California had antibodies to B. canis in 
1981-82. No foxes from the same region were seropositive 
in 1984. Antibodies to B. canis have also been detected 
sometimes in coyotes, but several surveys in this species, 
including some conducted within the last two decades, did 
not find any seropositive animals. 
In Canada, one study reported that 1.6% of dogs were 
seropositive by the 2-mercaptoethanol tube agglutination 
test in Quebec in the 1970s, and 0.6% had titers that 
indicated active infections. A study published in 1980 
found that 5% of dogs in southwestern Ontario were 
seropositive by RSAT, 1.5% of these samples had 
suspicious titers by tube agglutination, 0.05% had a positive 
titer by tube agglutination, and 0.3% were positive by 
immunoprecipitation.  
Several surveys have been published for Central and 
South America. One study from Mexico City reported that 
approximately 12% of the stray dogs tested had evidence of 
infection with B. canis in the 1970s . However, another 
survey from Mexico City found that 28% of the dogs tested 
were seropositive in an agglutination test, and B. canis was 
isolated from the blood of 1.6%. In 1980, 30.5% of stray 
dogs in a county of Buenos Aires were seropositive, and the 
organism was isolated from 6%. Additional studies of dogs 
in Buenos Aires were published in 2008 and 2009. One 
found antibodies to B. canis in 7.3% of the dogs tested in 
low income areas, and isolated the organism from 1.7% of 
these animals. The other reported that 15% of the dogs 
presented at a free neuter program were seropositive in the 
RSAT, and seropositivity was confirmed in 11% of these 
animals with an indirect ELISA. Almost all of the dogs at 
this clinic (98%) were female, and many of the seropositive 
animals came from areas where dogs are allowed to roam.  
A few surveys have been published from countries in 
Asia. In 1976-1977, antibodies to B. canis were found in 
11% of the dogs in some parts of Japan, and the organism 
was isolated from 37% of these seropositive animals. A 2008 
study from Japan reported that 2.5% of the dogs in an animal 
shelter were seropositive, using a microplate agglutination 
test. In a Chinese study from the 1980s, the seroprevalence 
rates for dogs from various provinces varied from 0.5% to 
43%, with higher seropositivity in older animals. In a study 
published in 2011 from India, the seroprevalence was 2.3% 
by 2-ME tube agglutination, 3% with a dot ELISA, 1.5% by 
AGID and 16% by indirect-ELISA.  
Occasional reports of clinical cases have been 
published from Europe, but few surveys have been 
conducted. In a survey from West Germany during the 
1970s, 1.8% of pet dogs had titers of 1:50, 2.9% had titers 
of 1:100, and 1.3% had titers of 1:200 in the tube 
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agglutination test. Using complement fixation, agar gel-
precipitation and indirect immunofluorescence, only 0.2% 
of these samples were confirmed positive. In Turkey, 
reported seroprevalence rates in dogs were 6.3% and 6.7% 
in two surveys from the 1980s, and 7.7% in a survey 
published in 2005. Using both PCR and culture, evidence of 
infection was found in 8.3% of lymph node samples 
collected from dogs that died in a Turkish city pound in 
2007-2008. 
There is very little information on the seroprevalence 
in Africa. In a recent study from Nigeria, 0.3% of the 
household dogs tested had antibodies to B. canis by RSAT. 
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